TY - JOUR A1 - Bonig, Halvard A1 - Kuçi, Zyrafete A1 - Kuçi, Selim A1 - Bakhtiar, Shahrzad A1 - Basu, Oliver A1 - Bug, Gesine A1 - Dennis, Mike A1 - Greil, Johann A1 - Barta, Aniko A1 - Kállay, Krisztián M. A1 - Lang, Peter A1 - Lucchini, Giovanna A1 - Pol, Raj A1 - Schulz, Ansgar A1 - Sykora, Karl-Walter A1 - Teichert von Luettichau, Irene A1 - Herter-Sprie, Grit A1 - Ashab Uddin, Mohammad A1 - Jenkin, Phil A1 - Alsultan, Abdulrahman A1 - Buechner, Jochen A1 - Stein, Jerry A1 - Kelemen, Agnes A1 - Jarisch, Andrea A1 - Soerensen, Jan A1 - Salzmann-Manrique, Emilia A1 - Hutter, Martin A1 - Schäfer, Richard A1 - Seifried, Erhard A1 - Paneesha, Shankara A1 - Novitzky-Basso, Igor A1 - Gefen, Aharon A1 - Nevo, Neta A1 - Beutel, Gernot A1 - Schlegel, Paul-Gerhardt A1 - Klingebiel, Thomas A1 - Bader, Peter T1 - Children and adults with Refractory acute Graft-versus-Host Disease respond to treatment with the Mesenchymal Stromal cell preparation “MSC-FFM”—Outcome report of 92 patients JF - Cells N2 - (1) Background: Refractory acute graft-versus-host disease (R-aGvHD) remains a leading cause of death after allogeneic stem cell transplantation. Survival rates of 15% after four years are currently achieved; deaths are only in part due to aGvHD itself, but mostly due to adverse effects of R-aGvHD treatment with immunosuppressive agents as these predispose patients to opportunistic infections and loss of graft-versus-leukemia surveillance resulting in relapse. Mesenchymal stromal cells (MSC) from different tissues and those generated by various protocols have been proposed as a remedy for R-aGvHD but the enthusiasm raised by initial reports has not been ubiquitously reproduced. (2) Methods: We previously reported on a unique MSC product, which was generated from pooled bone marrow mononuclear cells of multiple third-party donors. The products showed dose-to-dose equipotency and greater immunosuppressive capacity than individually expanded MSCs from the same donors. This product, MSC-FFM, has entered clinical routine in Germany where it is licensed with a national hospital exemption authorization. We previously reported satisfying initial clinical outcomes, which we are now updating. The data were collected in our post-approval pharmacovigilance program, i.e., this is not a clinical study and the data is high-level and non-monitored. (3) Results: Follow-up for 92 recipients of MSC-FFM was reported, 88 with GvHD ≥°III, one-third only steroid-refractory and two-thirds therapy resistant (refractory to steroids plus ≥2 additional lines of treatment). A median of three doses of MSC-FFM was administered without apparent toxicity. Overall response rates were 82% and 81% at the first and last evaluation, respectively. At six months, the estimated overall survival was 64%, while the cumulative incidence of death from underlying disease was 3%. (4) Conclusions: MSC-FFM promises to be a safe and efficient treatment for severe R-aGvHD. KW - graft-versus host KW - transplantation KW - mesenchymal stromal cell KW - cell therapy KW - hospital exemption KW - steroid-resistant aGvHD KW - refractory aGvHD Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-193878 SN - 2073-4409 VL - 8 IS - 12 ER - TY - JOUR A1 - Quast, Helmut A1 - Schmitt, Edeltraud A1 - Schäfer, Peter A1 - Heller, Eberhard A1 - Aldenkortt, Sven T1 - Synthesis and Thermolysis of a Chiral, Non-Racemic Iminoaziridine N2 - The 2-halo imidoyl chlorides 7 are obtained from the amide 5 and the 2-halo amides 6 by the action of phosphorus pentachloride and thionyl chloride, respectively. Non-racemic (S)-6a is converted into 7a which is racemic, however. The reaction of Lawesson's reagent with 6a furnishes the diastereomeric 1,3.2-thiazaphospholidine derivatives 15. Treatment of (S)-6a (98% eel with methyl triflate affords 2-chloro imidate 8 (95% eel which reacts with methanamine in the presence of methanammonium chloride to yield the 2-chloro amidine (S)-9a (90% eel. The 2-halo imidoyl halides 7a and b react with methanamine to produce the 2-halo amidines 9a and b. - Strong bases, e.g. potassium tert-butoxide or sodium hydride in the presence of catalytic amounts of tertbutyl alcohol, eliminate hydrogen chloride or bromide from the 2-halo amidines 9a and band (S)-9a to yield mixtures of Recently, we demonstrated that the formation of the chiral non-racemic aziridinone (R)-2 from the a-chloro amide (5)-1 by base-promoted dehydrochlorination[2) as well as the nucleophilic cleavage of the N-C(3) bond of (R)_2[3,4) occur with inversion of configuration, thus excluding the intervention of achiral (acyclic) intermediates. In the temperature range of lOO-170°C, however, slow racemization accompanies the thermolysis of (R)-2 and indicates the existence of an achiral or a racemic transient, e. g. (M)-3 + (P)-3. Indeed, high-level quantum-chemical calculations reveal that an activation energy of (170 ± 25) kJmol- 1 is required for the unimolecular ring opening of the parent aziridinone which affords a species of high diradical character[41. Subsequently, the unstable N-phenylaziridinone invoked in the decomposition of the (5)-2-bromopropananilide anion was shown to react with tert-butylamine or dimethylformamide with inversion of configuration at C(3)[51. Thus, the stereochemical evidence in the series of 3-alkylaziridinones excludes achiral (acyclic) aziridinone isomers as intermediates at low tempera tures [6J. Similar stereochemical studies are still missing in the related series of iminoaziridines. Therefore, we report on the synthesis and thermolysis of the diastereomeric chiral racemic (E)- and (Z)-(4)[71 and non-racemic iminoaziridines (E,R)- and (Z,R)-4. Racemic Iminoaziridines (E)- and (Z)-4 Though a photochemical route to the iminoaziridines (E)- and (Z)-4 has been devised more recently, i. e. the phothe 2-iminoaziridines (E)- and (Z)-4, and (E,R)- and (Z.R)-4 (83% eel, respectively. The 1.3-elimination of hydrogen bromide from 9b is diastereoselective at -30 to -40°C [(E)-4:(Z)-4 = <10:>90). The diastereomers equilibrate at 36°C with (kEZ + k ZE) = (5.92 ± 0.08) . 10-5 S-I (K = kEZlkzE = 0.428 ± 0.013). - The thermolysis of (E)- and (Z)-4 in [D61benzene solution yields the imine 16 and methyl isocyanide (17). The decomposition follows the first-order rate law. The following Arrhenius and Eyring parameters are calculated from five rate constants obtained in the temperature range of 70-110°C: Ea = (115.2 ± 0.4) kJmol-t, IgA = (12.06 ± 0.28), AH* = (112.1 ± 0.4) kJmol- l , AS'" = (-23.9 ± 0.7) JK-I mol-I, AGj73K = 121 kJmol-1 . The enantiomeric excess of the surviving fraction of (E,R)- and (Z.R)-4 is unchanged after two half-lives at 80°C. KW - Aziridines KW - 2-imino- KW - chiral KW - non-racemic KW - Imidoyl halides KW - 2-halo KW - Imidates KW - 2-chloro KW - 1 KW - 3 KW - 2-Thiazaphospholidines Y1 - 1994 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-38298 ER - TY - JOUR A1 - Bachmann, Friederike A1 - Schreder, Martin A1 - Engelhardt, Monika A1 - Langer, Christian A1 - Wolleschak, Denise A1 - Mügge, Lars Olof A1 - Dürk, Heinz A1 - Schäfer-Eckart, Kerstin A1 - Blau, Igor Wolfgang A1 - Gramatzki, Martin A1 - Liebisch, Peter A1 - Grube, Matthias A1 - Metzler, Ivana v. A1 - Bassermann, Florian A1 - Metzner, Bernd A1 - Röllig, Christoph A1 - Hertenstein, Bernd A1 - Khandanpour, Cyrus A1 - Dechow, Tobias A1 - Hebart, Holger A1 - Jung, Wolfram A1 - Theurich, Sebastian A1 - Maschmeyer, Georg A1 - Salwender, Hans A1 - Hess, Georg A1 - Bittrich, Max A1 - Rasche, Leo A1 - Brioli, Annamaria A1 - Eckardt, Kai-Uwe A1 - Straka, Christian A1 - Held, Swantje A1 - Einsele, Hermann A1 - Knop, Stefan T1 - Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM JF - Cancers N2 - Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group. KW - multiple myeloma KW - renal failure KW - kidney KW - bortezomib KW - lenalidomide KW - induction regimen Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234139 SN - 2072-6694 VL - 13 IS - 6 ER - TY - JOUR A1 - Bae, Soyeon A1 - Heidrich, Lea A1 - Levick, Shaun R. A1 - Gossner, Martin M. A1 - Seibold, Sebastian A1 - Weisser, Wolfgang W. A1 - Magdon, Paul A1 - Serebryanyk, Alla A1 - Bässler, Claus A1 - Schäfer, Deborah A1 - Schulze, Ernst-Detlef A1 - Doerfler, Inken A1 - Müller, Jörg A1 - Jung, Kirsten A1 - Heurich, Marco A1 - Fischer, Markus A1 - Roth, Nicolas A1 - Schall, Peter A1 - Boch, Steffen A1 - Wöllauer, Stephan A1 - Renner, Swen C. A1 - Müller, Jörg T1 - Dispersal ability, trophic position and body size mediate species turnover processes: Insights from a multi-taxa and multi-scale approach JF - Diversity and Distribution N2 - Aim: Despite increasing interest in β-diversity, that is the spatial and temporal turnover of species, the mechanisms underlying species turnover at different spatial scales are not fully understood, although they likely differ among different functional groups. We investigated the relative importance of dispersal limitations and the environmental filtering caused by vegetation for local, multi-taxa forest communities differing in their dispersal ability, trophic position and body size. Location: Temperate forests in five regions across Germany. Methods: In the inter-region analysis, the independent and shared effects of the regional spatial structure (regional species pool), landscape spatial structure (dispersal limitation) and environmental factors on species turnover were quantified with a 1-ha grain across 11 functional groups in up to 495 plots by variation partitioning. In the intra-region analysis, the relative importance of three environmental factors related to vegetation (herb and tree layer composition and forest physiognomy) and spatial structure for species turnover was determined. Results: In the inter-region analysis, over half of the explained variation in community composition (23% of the total explained 35%) was explained by the shared effects of several factors, indicative of spatially structured environmental filtering. Among the independent effects, environmental factors were the strongest on average over 11 groups, but the importance of landscape spatial structure increased for less dispersive functional groups. In the intra-region analysis, the independent effect of plant species composition had a stronger influence on species turnover than forest physiognomy, but the relative importance of the latter increased with increasing trophic position and body size. Main conclusions: Our study revealed that the mechanisms structuring assemblage composition are associated with the traits of functional groups. Hence, conservation frameworks targeting biodiversity of multiple groups should cover both environmental and biogeographical gradients. Within regions, forest management can enhance β-diversity particularly by diversifying tree species composition and forest physiognomy. KW - body size KW - dispersal ability KW - environmental filtering KW - forest physiognomy KW - neutral processes KW - plant composition KW - regional species pool KW - species turnover KW - trophic position KW - β-diversity Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-236117 VL - 27 IS - 3 ER - TY - JOUR A1 - Burns, Alan J. A1 - Goldstein, Allan M. A1 - Newgreen, Donald F. A1 - Stamp, Lincon A1 - Schäfer, Karl-Herbert A1 - Metzger, Marco A1 - Hotta, Ryo A1 - Young, Heather M. A1 - Andrews, Peter W. A1 - Thapar, Nikhil A1 - Belkind-Gerson, Jaime A1 - Bondurand, Nadege A1 - Bornstein, Joel C. A1 - Chan, Wood Yee A1 - Cheah, Kathryn A1 - Gershon, Michael D. A1 - Heuckeroth, Robert O. A1 - Hofstra, Robert M.W. A1 - Just, Lothar A1 - Kapur, Raj P. A1 - King, Sebastian K. A1 - McCann, Conor J. A1 - Nagy, Nandor A1 - Ngan, Elly A1 - Obermayr, Florian A1 - Pachnis, Vassilis A1 - Pasricha, Pankaj J. A1 - Sham, Mai Har A1 - Tam, Paul A1 - Vanden Berghe, Pieter T1 - White paper on guidelines concerning enteric nervous system stem cell therapy for enteric neuropathies JF - Developmental Biology N2 - Over the last 20 years, there has been increasing focus on the development of novel stem cell based therapies for the treatment of disorders and diseases affecting the enteric nervous system (ENS) of the gastrointestinal tract (so-called enteric neuropathies). Here, the idea is that ENS progenitor/stem cells could be transplanted into the gut wall to replace the damaged or absent neurons and glia of the ENS. This White Paper sets out experts' views on the commonly used methods and approaches to identify, isolate, purify, expand and optimize ENS stem cells, transplant them into the bowel, and assess transplant success, including restoration of gut function. We also highlight obstacles that must be overcome in order to progress from successful preclinical studies in animal models to ENS stem cell therapies in the clinic. KW - Neural crest cells KW - Rat mynteric plexus KW - Intestinal pseudoobstruction KW - Hypertrophic pyloric-stenosis KW - Hirschsprung disease liability KW - Slow-transit constipation KW - Oxide synthase gene KW - Term follow-up KW - Nitric-oxide KW - In-vivo KW - Enteric nervous system KW - Enteric neuropathies KW - Stem cells KW - Cell replacement therapy KW - Hirschsprung disease Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187415 VL - 417 IS - 2 ER - TY - JOUR A1 - Schäfer, Nadine A1 - Friedrich, Maximilian A1 - Jørgensen, Morten Egevang A1 - Kollert, Sina A1 - Koepsell, Hermann A1 - Wischmeyer, Erhard A1 - Lesch, Klaus-Peter A1 - Geiger, Dietmar A1 - Döring, Frank T1 - Functional analysis of a triplet deletion in the gene encoding the sodium glucose transporter 3, a potential risk factor for ADHD JF - PLoS ONE N2 - Sodium-glucose transporters (SGLT) belong to the solute carrier 5 family, which is characterized by sodium dependent transport of sugars and other solutes. In contrast, the human SGLT3 (hSGLT3) isoform, encoded by SLC5A4, acts as a glucose sensor that does not transport sugar but induces membrane depolarization by Na\(^{+}\) currents upon ligand binding. Whole-exome sequencing (WES) of several extended pedigrees with high density of attention-deficit/hyperactivity disorder (ADHD) identified a triplet ATG deletion in SLC5A4 leading to a single amino acid loss (ΔM500) in the hSGLT3 protein imperfectly co-segregating with the clinical phenotype of ADHD. Since mutations in homologous domains of hSGLT1 and hSGLT2 were found to affect intestinal and renal function, respectively, we analyzed the functional properties of hSGLT3[wt] and [ΔM500] by voltage clamp and current clamp recordings from cRNA-injected Xenopus laevis oocytes. The cation conductance of hSGLT3[wt] was activated by application of glucose or the specific agonist 1-desoxynojirimycin (DNJ) as revealed by inward currents in the voltage clamp configuration and cell depolarization in the current clamp mode. Almost no currents and changes in membrane potential were observed when glucose or DNJ were applied to hSGLT3[ΔM500]-injected oocytes, demonstrating a loss of function by this amino acid deletion in hSGLT3. To monitor membrane targeting of wt and mutant hSGLT3, fusion constructs with YFP were generated, heterologously expressed in Xenopus laevis oocytes and analyzed for membrane fluorescence by confocal microscopy. In comparison to hSGLT3[wt] the fluorescent signal of mutant [ΔM500] was reduced by 43% indicating that the mutant phenotype might mainly result from inaccurate membrane targeting. As revealed by homology modeling, residue M500 is located in TM11 suggesting that in addition to the core structure (TM1-TM10) of the transporter, the surrounding TMs are equally crucial for transport/sensor function. In conclusion, our findings indicate that the deletion [ΔM500] in hSGLT3 inhibits membrane targeting and thus largely disrupts glucose-induced sodium conductance, which may, in interaction with other ADHD risk-related gene variants, influence the risk for ADHD in deletion carriers. KW - Xenopus laevis oocytes KW - ADHD KW - glucose KW - cell membranes KW - membrane proteins KW - membrane potential KW - crystal structure KW - amino acid analysis Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176495 VL - 13 IS - 10 ER -